Diaceutics PLC Notice of Capital Markets Day (9510A)
07 Junio 2021 - 1:00AM
UK Regulatory
TIDMDXRX
RNS Number : 9510A
Diaceutics PLC
07 June 2021
7 June 2021
Diaceutics PLC
("Diaceutics" or "the Group")
Notice of Capital Markets Day
Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation
company, announces that it will be hosting a virtual Capital
Markets Day ("CMD") for investors and equity analysts on Wednesday
16(th) June 2021, starting at 13:00pm BST.
The event will be hosted by Group CEO, Peter Keeling, and will
include a series of presentations, a demonstration of the DXRX SaaS
platform, views from an industry expert panel including:
-- Pharmaceutical Partner: a senior executive within one of the
world's top five pharmaceutical companies
-- Laboratory Partner: Professor Giancarlo Pruneri, Head of
Pathology Fondazione IRCCS Istituto Nazionale Tumori, Milan
-- Key Opinion Leader: Dr Avi Kulkarni, SVP and R&D leader
at Nasdaq listed technology firm Cognizant
In addition, there will be a strategic update from the Company,
along with a live Q&A.
A video replay of the presentation will be available via the
Group's website post-event.
If you are interested in attending or have any questions
relating to the Diaceutics Capital Markets Day please contact
diaceutics@almapr.co.uk
Enquiries:
Diaceutics PLC www.diaceutics.com
Peter Keeling, Chief Executive Officer via Alma PR
Philip White, Chief Financial Officer
Stifel Nicolaus Europe Limited (Nominated
Adviser and Broker)
Ben Maddison
Stewart Wallace +44 (0)20 7710
Nick Adams 7600
Alma PR Tel: +44 (0)20
Caroline Forde 3405 0205
Robyn Fisher diaceutics@almapr.co.uk
Kieran Breheny
About Diaceutics
At Diaceutics we believe that every patient should have access
to the right treatment at the right time. We provide the world's
leading pharmaceutical companies with an end-to-end solution for
the launch of precision medicine diagnostics enabled by DXRX - The
Diagnostic Network(R).
DXRX is the world's first diagnostic commercialisation platform
for precision medicine, integrating multiple pipelines of
real-world diagnostic testing data from a global network of
laboratories.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCFFFSIREIEIIL
(END) Dow Jones Newswires
June 07, 2021 02:00 ET (06:00 GMT)
Diaceutics (LSE:DXRX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Diaceutics (LSE:DXRX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024